Mari Cristina, Pierroz Vanessa, Ferrari Stefano, Gasser Gilles
Department of Chemistry , University of Zurich , Winterthurerstrasse 190 , CH-8057 Zurich , Switzerland . Email:
Institute of Molecular Cancer Research , University of Zurich , Winterthurerstrasse 190 , CH-8057 Zurich , Switzerland.
Chem Sci. 2015 May 1;6(5):2660-2686. doi: 10.1039/c4sc03759f. Epub 2015 Jan 13.
The synergistic action of light, oxygen and a photosensitizer (PS) has found applications for decades in medicine under the name of photodynamic therapy (PDT) for the treatment of skin diseases and, more recently, for the treatment of cancer. However, of the thirteen PSs currently approved for the treatment of cancer over more than 10 countries, only two contain a metal ion. This fact is rather surprising considering that nowadays around 50% of conventional chemotherapies involve the use of cisplatin and other platinum-containing drugs. In this perspective article, we review the opportunities brought by the use of Ru(ii) complexes as PSs in PDT. In addition, we also present the recent achievements in the application of Ru(ii) complexes in photoactivated chemotherapy (PACT). In this strategy, the presence of oxygen is not required to achieve cell toxicity. This is of significance since tumors are generally hypoxic. Importantly, this perspective article focuses particularly on the Ru(ii) complexes for which an biological evaluation has been performed and the mechanism of action (partially) unveiled.
光、氧和光敏剂(PS)的协同作用以光动力疗法(PDT)的名义在医学领域已有数十年的应用,用于治疗皮肤疾病,最近也用于治疗癌症。然而,在目前已在10多个国家获批用于癌症治疗的13种光敏剂中,只有两种含有金属离子。考虑到如今约50%的传统化疗涉及使用顺铂和其他含铂药物,这一事实相当令人惊讶。在这篇观点文章中,我们综述了使用钌(II)配合物作为光动力疗法中的光敏剂所带来的机遇。此外,我们还介绍了钌(II)配合物在光活化化疗(PACT)应用中的最新成果。在这种策略中,实现细胞毒性不需要氧气的存在。这具有重要意义,因为肿瘤通常是缺氧的。重要的是,这篇观点文章特别关注已进行生物学评估且(部分)揭示了作用机制的钌(II)配合物。